MedTrace Logo

Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy

NCT00742482 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2025-02-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of three doses of HL 10 given at fixed time intervals compared to standard therapy

Conditions

  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome

Interventions

DRUG

HL 10

Freeze dried HL 10

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Jozef Kesecioglu, MD, PhD · Anaesthesist-Intensivist, Department of Intensive Care Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2005-01-31
Completion
2005-06-30

Countries

  • Austria
  • Belgium
  • Canada
  • Denmark
  • Finland
  • France
  • Germany
  • Netherlands
  • Norway
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00742482 on ClinicalTrials.gov